SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?


To: Mel Spivak who wrote (271)7/18/1998 8:49:00 PM
From: kas1  Read Replies (2) | Respond to of 642
 
yeah, wonder if the analyst really was writing about zeldox, or if it's just a typo? too bad for pfizer, zeldox was rejected by the fda, while zyprexa continues to gain market share. zyprexa could be for schizophrenia (and related psychotic disorders) what prozac is/was for depression... perhaps for a whole wave of people going to get diagnosis and treatment instead of suffering secretly (or spending decades on the couch).